{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:01:23Z","timestamp":1762254083127},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.7759\/cureus.22751","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T20:49:25Z","timestamp":1646167765000},"source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab-Induced Autoimmune Thyroid Dysfunction"],"prefix":"10.7759","author":[{"given":"Sharanniyan","family":"Ragavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Elhelw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Kyriacou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akheel","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck T","year":"2015","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015, 16:16414-39. 10.3390\/ijms160716414","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li Z","year":"2018","unstructured":"Li Z, Richards S, Surks HK, Jacobs A, Panzara MA. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018, 194:295-314. 10.1111\/cei.13208","journal-title":"Clin Exp Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8822-y","article-title":"Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations","volume":"265","author":"Devonshire V","year":"2018","unstructured":"Devonshire V, Phillips R, Wass H, Da Roza G, Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol. 2018, 265:2494-505. 10.1007\/s00415-018-8822-y","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio L","year":"2020","unstructured":"Scappaticcio L, Castellana M, Virili C, et al.. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest. 2020, 43:219-29. 10.1007\/s40618-019-01105-7","journal-title":"J Endocrinol Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani N","year":"2018","unstructured":"Pariani N, Willis M, Muller I, et al.. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018, 103:3010-8. 10.1210\/jc.2018-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli A","year":"2015","unstructured":"Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015, 14:174-80. 10.1016\/j.autrev.2014.10.016","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007","article-title":"Hashimoto thyroiditis: clinical and diagnostic criteria","volume":"13","author":"Caturegli P","year":"2014","unstructured":"Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014, 13:391-7. 10.1016\/j.autrev.2014.01.007","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EC-18-0082","article-title":"Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test","volume":"7","author":"Bell L","year":"2018","unstructured":"Bell L, Hunter AL, Kyriacou A, Mukherjee A, Syed AA. Clinical diagnosis of Graves' or non-Graves' hyperthyroidism compared to TSH receptor antibody test. Endocr Connect. 2018, 7:504-10. 10.1530\/EC-18-0082","journal-title":"Endocr Connect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2011.02.006","article-title":"The role of TSH receptor antibodies in the management of Graves' disease","volume":"22","author":"Matthews DC","year":"2011","unstructured":"Matthews DC, Syed AA. The role of TSH receptor antibodies in the management of Graves' disease. Eur J Intern Med. 2011, 22:213-6. 10.1016\/j.ejim.2011.02.006","journal-title":"Eur J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves' disease","volume":"6","author":"Davies TF","year":"2020","unstructured":"Davies TF, Andersen S, Latif R, et al.. Graves' disease. Nat Rev Dis Primers. 2020, 6:52. 10.1038\/s41572-020-0184-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00254","article-title":"Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response","volume":"8","author":"Rotondi M","year":"2017","unstructured":"Rotondi M, Molteni M, Leporati P, Capelli V, Marin\u00f2 M, Chiovato L. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-receptor immune response. Front Endocrinol (Lausanne). 2017, 8:254. 10.3389\/fendo.2017.00254","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000500881","article-title":"2019 European Thyroid Association guidelines on the management of thyroid dysfunction following immune reconstitution therapy","volume":"8","author":"Muller I","year":"2019","unstructured":"Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, Dayan CM. 2019 European Thyroid Association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J. 2019, 8:173-85. 10.1159\/000500881","journal-title":"Eur Thyroid J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series","volume":"33","author":"Roos JC","year":"2019","unstructured":"Roos JC, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series. Eye (Lond). 2019, 33:223-9. 10.1038\/s41433-018-0282-1","journal-title":"Eye (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/85735-alemtuzumab-induced-autoimmune-thyroid-dysfunction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:00Z","timestamp":1707507540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/85735-alemtuzumab-induced-autoimmune-thyroid-dysfunction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.22751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}